Drug Trial Radar · NCT05594095
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
620
Planned (sponsor's estimate)
Start
Dec 30, 2022
Primary completion
Dec 1, 2025
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking University Cancer Hospital & Institute; First Hospital of China Medical University; Sun Yat-sen University; First Affiliated Hospital Xi'an Jiaotong University; Chongqing University Cancer Hospital; Northern Jiangsu People's Hospital; Fujian Medical University Union Hospital; Ningbo Medical Center Lihuili Hospital; Shanghai First Maternity and Infant Hospital; Shanghai 6th People's Hospital; Affiliated Hospital of Nantong University; Nanchang Third Hospital; Liaoning Cancer Hospital & Institute; The First Hospital of Jilin University
- First posted
- Oct 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.
Conditions
- Breast Neoplasm
- Breast Cancer
- Hormone Receptor Positive Tumor
- HER2-negative Breast Cancer
- Advanced Breast Cancer
Interventions
PIK3CA inhibitorDrug
PIK3CA inhibitor
AKT inhibitorDrug
AKT inhibitor
CarrelizumabDrug
Pd-1 mab
FamitinibDrug
VEGFR inhibitor
FluzoparibDrug
PARP inhibitor
DalpiciclibDrug
CDK4/6 inhibitor
SHR-A1811Drug
HER2 ADC
EverolimusDrug
mTOR inhibior
Aromatase Inhibitors or FulvestrantDrug
Letrozole/Anastrozole/Exemestane or Fulvestrant
GoserelinDrug
For premenopause
TPCDrug
Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
SorafenibDrug
RTK Inhibitor
ApatinibDrug
Apatinib 250mg po qd
SHR-A1921Drug
TROP2 ADC
SHR-A2102Drug
NECTIN4 ADC
SHR-A2009Drug
HER3 ADC
SHR-1167Drug
PARP1i
SHR-6209Drug
CDK4i
bevacizumabDrug
bevacizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR)Time frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 3 years)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Breast cancer institute of Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.